AADvac 1

Drug Profile

AADvac 1

Alternative Names: AADvac-1; Alzheimer's disease vaccine - Axon Neuroscience; Axon peptide 108 conjugated to KLH; Axon peptide 108 coupled to KLH

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Axon Neuroscience
  • Class Alzheimer vaccines
  • Mechanism of Action Immunostimulants; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease
  • Phase I Aphasia

Most Recent Events

  • 31 Jul 2017 Phase-I clinical trials in Aphasia in Germany (IV) (NCT03174886)
  • 17 Jul 2017 Axon Neuroscience completes enrolment in the phase II ADAMANT trial for Alzheimer's Disease in Austria, Czech Republic, Slovakia, Slovenia, Sweden, Poland, Romania and Germany (NCT02579252)
  • 03 Apr 2017 AXON Neuroscience and German FTLD Consortium plan a pilot phase I trial for Aphasia (non-fluent variant of Primary Progressive Aphasia (nfvPPA)) in Germany (NCT03174886)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top